These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37831226)

  • 21. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic landscape and prognosis of conjunctival melanoma in Chinese patients.
    Shi H; Tian H; Zhu T; Chen J; Jia S; Zong C; Liao Q; Ruan J; Ge S; Rao Y; Dong M; Jia R; Li Y; Xu S; Fan X
    Br J Ophthalmol; 2024 Aug; 108(9):1306-1312. PubMed ID: 38383070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.
    Beaudoux O; Oudart JB; Riffaud L; Visseaux L; Marchal A; Lebre AS; Grange F
    Mol Diagn Ther; 2022 Mar; 26(2):189-202. PubMed ID: 35195858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
    Riobello C; Casanueva Muruais R; Suárez-Fernández L; García-Marín R; Cabal VN; Blanco-Lorenzo V; Franchi A; Laco J; López F; Llorente JL; Hermsen MA
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):88-96. PubMed ID: 34547192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients.
    Lally SE; Milman T; Orloff M; Dalvin LA; Eberhart CG; Heaphy CM; Rodriguez FJ; Lin CC; Dockery PW; Shields JA; Shields CL
    Ophthalmology; 2022 Jun; 129(6):679-693. PubMed ID: 35085662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
    Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B
    Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
    Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
    Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-related next-generation sequencing mutational analysis in 1196 melanomas.
    Santamaria-Barria JA; Matsuba C; Khader A; Scholar AJ; Garland-Kledzik M; Fischer TD; Essner R; Salomon MP; Mammen JMV; Goldfarb M
    J Surg Oncol; 2023 Jun; 127(7):1187-1195. PubMed ID: 36938777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites.
    Sekine S; Nakanishi Y; Ogawa R; Kouda S; Kanai Y
    Virchows Arch; 2009 May; 454(5):513-7. PubMed ID: 19319568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.
    Quek C; Rawson RV; Ferguson PM; Shang P; Silva I; Saw RPM; Shannon K; Thompson JF; Hayward NK; Long GV; Mann GJ; Scolyer RA; Wilmott JS
    Oncotarget; 2019 Jan; 10(9):930-941. PubMed ID: 30847022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.